We feel now is a pretty good time to analyse MDxHealth SA's (NASDAQ:MDXH) business as it appears the company may be on the cusp of a considerable accomplishment. MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The US$170m market-cap company posted a loss in its most recent financial year of US$38m and a latest trailing-twelve-month loss of US$31m shrinking the gap between loss and breakeven. As path to profitability is the topic on MDxHealth's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Consensus from 5 of the American Biotechs analysts is that MDxHealth is on the verge of breakeven. They expect the company to post a final loss in 2026, before turning a profit of US$2.3m in 2027. Therefore, the company is expected to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2027? Working backwards from analyst estimates, it turns out that they expect the company to grow 81% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving MDxHealth's growth isn’t the focus of this broad overview, but, keep in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Before we wrap up, there’s one issue worth mentioning. MDxHealth currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

There are key fundamentals of MDxHealth which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at MDxHealth, take a look at MDxHealth's company page on Simply Wall St. We've also compiled a list of pertinent factors you should further examine:

1. Valuation: What is MDxHealth worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether MDxHealth is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on MDxHealth’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.